News An aura of adult migraine hope as NICE recommends Vyepti Lundbeck’s eptinezumab receives NICE recommendation for the prevention of migraine in adults.
News Third death reported with a Sarepta gene therapy A third fatality has been recorded among patients receiving treatment with a Sarepta gene therapy, adding to the troubles being faced by the company.
Market Access The value of a partner, globally and locally A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face
